You are here: Industry Insights > Aimmune Therapeutics

News List

Nestlé to acquire biopharma company, Aimmune Therapeutics expresspharma
September 01, 2020
Aimmune's Palforzia is an FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts.
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting firstwordpharma
June 12, 2019
Cost per QALY, or quality-adjusted life year, measures the economic value of a health care intervention; the lower the cost per QALY, the higher the value of the treatment.
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17 drugs
December 24, 2018
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a ....
Aimmune Therapeutics to collaborate with Sanofi/Regeneron biospectrumasia
October 18, 2017
The three companies are planning a 2018 midstage test of AR101 with adjunctive dupilumab in peanut-allergic patients